Status:
COMPLETED
A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
Lead Sponsor:
Mati Therapeutics Inc.
Conditions:
Glaucoma
Ocular Hypertension (OH)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy, safety and duration of the L-PPDS (latanoprost punctal plug delivery system) at different dose levels.
Eligibility Criteria
Inclusion
- Male or female at least 18 years old
- Diagnosis of bilateral open angle glaucoma or ocular hypertension
- Unmedicated IOP must be ≥22mm Hg
Exclusion
- Any significant vision loss in the last year
- No contact lens use for the length of the study
- Abnormal eye lids, eye infection, or diseases to the eye
- Recent eye surgery
- Uncontrolled medication conditions
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT01481051
Start Date
November 1 2011
End Date
September 1 2012
Last Update
September 26 2013
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Sall Research Medical Center, Inc
Artesia, California, United States, 90701
2
Wolstan & Goldberg Eye Associates
Los Angeles, California, United States, 90505
3
West Coast Eye Care Associates
San Diego, California, United States, 92115
4
Coastal Research Associates, LLC
Roswell, Georgia, United States, 30076